CFHR2

Across TCGA pan-cancer cohorts, CFHR2 RNA is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CFHR2 data layer compared with 4 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher CFHR2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CFHR2 expression acts as an unfavorable survival marker, although some lineages such as LIHC and SCLC show a favorable association.

CHOL, PAAD, and LIHC are the cancer types where CFHR2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Tertile	II,III,IV	0.187	0.833	.001	49	view →
PAAD	DFS	Tertile	All	0.303	0.498	.016	45	view →
LIHC	OS	Median	II,III,IV	0.693	0.524	.011	14	view →
SCLC	OS	Tertile	III,IV	1.000	0.556	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CFHR2–CHOL (OS)

Open the CHOL breakdown →